This recent conference in Zürich, sponsored by the Foundation for the National Institutes of Health (FNIH), the Wellcome Trust (UK) and the Swiss Federal Institute of Technology in Zürich (ETH…
Read More
While the breakneck pace of technological innovation has affected nearly every facet of modern life, the opportunities it has created in clinical research have been game-changing. This has been particularly…
When our Chief Scientific Officer, Dr. Elena Izmailova, founded what was then the “Women of Koneksa” group, our company had fewer than 30 people, most of whom were men, and…
At the recent Digital Biomarkers and Clinical Measures in Neurology meeting, Koneksa was honored to speak on the importance of digital biomarkers to research into central nervous system (CNS) conditions,…
If you’re reading this, it’s overwhelmingly likely that you have a smartphone, and possibly a fitness tracker. Digital Health Technologies (DHTs) like these can help us learn more about our…
Koneksa CMO John Wagner, MD, Ph.D. discussed the benefits and challenges of using biomarkers and translational science in clinical development programs at an FDA workshop hosted by the Duke-Margolis Center…
Koneksa’s unique expertise in designing, developing, and deploying digital health technology (DHT)-enabled biomarkers in clinical trials, and our experience analyzing the corresponding data, can provide value to your product’s journey….
This week, the American Society of Clinical Pharmacology and Therapeutics (ASCPT) held a two-day satellite session dedicated to discussing the challenges of conducting clinical trials in patient populations of limited…
Very often, suboptimal adherence to data collection procedures and/or a study intervention is a cause of a failed clinical trial. Recently, Koneksa’s Chief Scientific Officer, Dr. Elena Izmailova, who is…
“Standing on the shoulders of giants,” as Newton put it, is the foundation of science. That’s especially true in biomarker science, as we take decades of experience with laboratory biomarkers…
